Treatment | < 34 weeks gestation | < 37 weeks gestation | ||
---|---|---|---|---|
bcOR (95%CI) | caOR (95%CI) | cOR (95%CI) | aOR (95%CI) | |
Among all participants | ||||
IM 17-OHPC | 1.89 (1.07, 3.45) | 1.79 (0.89, 3.75) | 1.43 (0.98, 2.08 | 1.47 (0.94, 2.31) |
Vaginal Progesterone | 0.41 (0.25, 3.37) | 1.06 (0.23, 3.62) | 0.58 (0.21, 1.35) | 0.59 (0.21, 1.46) |
Among those without short cervix | ||||
IM 17-OHPC | 1.51 (0.79, 2.98) | 1.71 (0.80, 3.84) | 1.22 (0.80, 1.87) | 1.36 (0.84, 2.20) |
Vaginal Progesterone | 0.94 (0.14, 3.53) | 1.24 (0.18, 4.98) | 0.54 (0.15, 1.44) | 0.64 (0.18, 1.78) |
Among those with short cervix | ||||
IM 17-OHPC | 1.86 (0.42, 13.1) | 2.24 (0.31, 45.50) | 2.88 (0.84, 11.6) | 5.61 (1.16, 42.9) |
Vaginal Progesterone | 0.72 (0.03, 8.70) | 1.22 (0.04, 36.73) | 0.69 (0.08, 4.49) | 1.45 (0.13, 16.3) |